Industry News

Our news page will keep you informed of press releases and news articles on rapid and alternative microbiological method technologies and updates from technology suppliers.

Please click here to submit your news.

OpGen Partners with NY State Department of Health and Merck’s ILÚM Health Solutions to Detect Antimicrobial-Resistant Infections

OpGen, Inc. announced a groundbreaking collaboration with the New York State Department of Health (“DOH”) and ILÚM Health Solutions, LLC (“ILÚM”), a wholly owned subsidiary of Merck’s Healthcare Services and Solutions, to develop a state-of-the-art research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions statewide. OpGen will work together with DOH’s Wadsworth Center and ILÚM to develop an infectious disease digital health and precision medicine platform that connects healthcare institutions to DOH and uses genomic microbiology for statewide surveillance and control of antimicrobial resistance.

The DOH, ILÚM and OpGen will work collaboratively to build a sustainable, flexible infectious diseases reporting, tracking and surveillance tool for antimicrobial resistance that can be applied across New York State. The goal of this project is to improve patient outcomes and save healthcare dollars by integrating real-time epidemiologic surveillance with rapid delivery of resistance results to care-givers via web-based and mobile platforms. ILÚM is leading the project with the implementation of its technology platform. OpGen is providing its Acuitas® AMR Gene Panel for rapid detection of multidrug-resistant bacterial pathogens along with its Acuitas Lighthouse® Software for high resolution pathogen tracking.

“We are proud to be a part of this groundbreaking initiative throughout the State of New York, and to collaborate with Wadsworth and ILÚM to help develop the blueprint for how governments and healthcare facilities can detect, track, and manage antimicrobial-resistant infections,” said Evan Jones, CEO, OpGen. “As part of the collaboration, OpGen will receive a $1.5 million contract for the 12-month demonstration portion of the project, with the potential for full implementation during the next five years, should certain milestones be achieved by all parties involved. We look forward to working with the Wadsworth Laboratories and to serving the people of the State of New York.”

The precision medicine solutions provided by OpGen and ILÚM to accomplish the goals of the project are:
  • The OpGen Acuitas AMR Gene Panel u.5.47, a distributed, rapid diagnostics platform capable of detection and identification of multidrug-resistant bacterial pathogens in under three hours and for use with the Acuitas Lighthouse Software.  Together, these products can rapidly identify and locate antibiotic resistance threats in healthcare institutions and networks.  Both systems are commercially available for Research Use Only (RUO) and are anticipated to be submitted for FDA clearance after completion of ongoing and planned clinical trials. In future iterations, OpGen’s Acuitas technologies are anticipated to provide custom testing solutions to supplement evolving Wadsworth Laboratory testing and New York State’s DOH surveillance needs.
  • The OpGen Acuitas Lighthouse Software includes Acuitas Lighthouse epidemiology dashboards with high-resolution pathogen tracking through healthcare facilities, to cities, regions, as well as the entire state. 
  • ILÚM’s technology platform, a Commercial Off The Shelf (COTS) solution which assembles and streams analyzed health data from across locations and health care systems. This data includes laboratory test results, pharmacy, orders, and ADT (admissions, discharges, transfers). The platform offers patient and program-specific data analytics and visualization capabilities to users via a web application and a mobile device application.  Also, it enables case browsing, patient monitoring, detection and prioritization and performance monitoring and reporting for disease management, including actionable insights in support of quality improvement efforts, disease surveillance, pathway adherence, and ultimately impacting outcomes.
New York State Health Commissioner Dr. Howard A. Zucker said, "Under Governor Cuomo's leadership, New York State is setting the standard in addressing the threat of antimicrobial resistance.  New York's Wadsworth Center is uniquely qualified to partner with OpGen and ILÚM Health Solutions as part of our response to this public health concern."

Post a Comment

Previous Post Next Post

Contact Form